Biosyntia
EMEA
Copenhagen
,
Denmark
Startup
FOUNDED
2012
HEADCOUNT
2-20
FUNDING
Series B
Keywords:
precision_fermentation, synthetic_biology, metabolic_engineering, HTP_screening, vitamins, nutraceuticals, cosmetics
BUSINESS
Produces natural vitamins and bioactive ingredients via precision fermentation and metabolic engineering as alternatives to chemical synthesis for nutraceuticals, food, and personal care. Biosyntia, founded in 2012 as a spin-out from DTU's Centre for Biosustainability, is based in Copenhagen, Denmark. The company has commercial partnerships with Givaudan and Wacker. Its first commercial product is BIO-B7, a fermentation-derived biotin (vitamin B7) for dietary supplements, food, and beauty applications
BIOTECH INVOLVEMENT
Core: proprietary microbial strains and fermentation platform for high-purity bio-based production. The company has all critical capabilities in-house; microbial engineering, fermentation optimization, product purification, formulation, and sales. They employ a proprietary high-throughput screening platform (Biosynthetic Selections™) to accelerate strain development, and are building a pipeline of fermentation-derived vitamins and plant bioactives as replacements for petrochemically synthesized products. ~20 people, focused on precision fermentation of small molecules.
TECHNOLOGY PLATFORM
Precision fermentation; metabolic engineering; strain engineering
PRIMARY PRODUCTS
BIO-B7 (natural biotin) and other B-vitamins/bioactives